TrialAnnals of hematology2024

Addition of ruxolitinib and decitabine to modified busulfan/cyclophosphamide conditioning regimen for prophylaxis relapse in high-risk acute myeloid leukemia: the phase 2 prospective study.

Yujun Wei et al.PubMed ↗Publisher ↗

No numbers read from the abstract.